Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

Completed

• Conditions: Colonoscopy; Post-polypectomy Bleeding; Anti-platelet Therapy

• Registration Number: NCT01647568
• Lead Sponsor: Dallas VA Medical Center

Brief Summary

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.

Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-12
• Primary Completion: 2012-03
• Status Verified: 2012-07
• Study First Submitted: 2012-07-19
• Study First Submitted QC: 2012-07-19
• Last Update Submitted: 2012-07-19
• Study First Posted: 2012-07-23
• Last Update Posted: 2012-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 715

Inclusion Criteria

• Patients presenting to the GI lab for elective colonoscopy

Exclusion Criteria

• Patients on Coumadin or other anti-coagulants
• Patients with Inflammatory Bowel Disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Dallas VA Medical Center; 🇺🇸 Dallas, Texas, United States